## **DECLARATION** FOR PATENT APPLICATION

As a below named inventor(s), I/We hereby declare that:

92290 Chatenay Malabry (France)

My/Our residence(s), post office address(es) and citizenship(s) are as stated below my name(s). I/We verily believe I am/we are the original, first and sole/joint inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF A PRODUCT WHICH ACTIVATIVES DOPAMINERGI NEUROTRANSMISSION IN THE BRAIN, THE PHARMACEUTICAL COMPOSITIONS

	COMPRISING THEM A	ND THEIR USE IN TH	E TREATMENT OF PARKINSON'S DISEASE
	and the specification of w (check one)	was filed on and was ame was described	ereto (Aventis Docket No. <b>ST01023 US CNT</b> ) as U.S. Application Number nded on (if applicable). d and claimed in PCT Int'l Application Number filed on as amended under PCT Article 19 on (if any).
	including the claims as an I/We acknowledge the du	nended by any amendme	Patent and Trademark Office all information known to me/us to
$\boxtimes$	application(s) for patent of least one other country of the application on which	r inventor's certificate, or there than the United States priority is claimed. I/We	tle 35, United States Code §119(a)-(d) or 365 (b) of any foreign 365(a) of any PCT international application which designated at s of America, listed below and having a filing date before that of have also identified below any foreign application for patent or of the application on which priority is claimed:
Foreign Priority:	<u>0111200</u> Number	France Country	29/August/2001 Day/Month/Year Filed
Prior Foreign Appln(s):	Number	Country	Day/Month/Year Filed
	I/We hereby claim the application(s) listed belo	benefit under Title 35, L w:	Inited States Code §119(e) of any United States Provisional
	Number	Filing Date	
⊠	application(s) or internati matter of each of the clair provided by the first par information which is mat	onal application designat ns of this application is no agraph of Title 35, Unite erial to patentability as o	United States Code §120 or 365(c) of any United States ing the United States listed below and, insofar as the subject of disclosed in the prior United States application in the manner d States Code §112, I/We acknowledge the duty to disclose defined in Title 37, Code of Federal Regulations §1.56 which or application and the national or PCT international filing date of
	PCT/FR02/02946 Application Serial No.	August 28, 2002 Filing Date	Pending Status (Patented, Pending)
and belief ar and the like	e believed to be true; and so made are punishable b tatements may jeopardize	further that these stateme y fine or imprisonment, or	knowledge are true and that all statements made on information ents were made with the knowledge that willful false statements both, under Title 18, United States code §1001, and that such ion or any patent issued thereon.
1. Full name: .]	ésus BENAVIDES		2. Full name: Daniel BOCCIO
Date:	zenship: <b>Spain</b>		Signature:  Date:  Country of Civing Property
	atenay Malabry, France		Country of Citizenship: France Residence: Pringy, France
	(City, State/City, and Count	ry only)	Residence: Pringy, France (City, State/City, and Country only)
P. O. Address:	105 rue Anatole France		P. O. Address: 27 rue de Lourdeau

77310 Pringy (France)

3. Full name: <u>Yvette HENIN</u>	4. Full name: Odile PIOT-GROSJEAN
Signature:	Signature:
Date:	
Country of Citizenship: France	- 0011 AT
Residence: Paris, France	Residence: Choisy Le Roi, France
(City, State/City, and Country only)	(City, State/City, and Country only)
P. O. Address: 12, rue duchefdelaville	P. O. Address: 4 rue Jean-Baptiste Clément
75013 Paris (France)	94600 Choisy Le Roi (France)
5. Full name:	6. Full name:
Signature:	Signature:
	Signature: Date:
Signature:	Signature: Date: Country of Citizenship: Residence:
Signature:	Signature: Date:

Customer No. 005487

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206
P.O. Box 6800
Mail Code D-303A
Bridgewater, NJ 08807-0800
Telephone (908) 231-3364
Telefax (908) 231-2626

Aventis Docket No. ST01023 US CNT